These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 23362162)

  • 21. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
    Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
    Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.
    Miyamae Y; Shimizu K; Mitani Y; Araki T; Kawai Y; Baba M; Kakegawa S; Sugano M; Kaira K; Lezhava A; Hayashizaki Y; Yamamoto K; Takeyoshi I
    J Mol Diagn; 2010 Mar; 12(2):257-64. PubMed ID: 20093389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
    Ma W; Brodie S; Agersborg S; Funari VA; Albitar M
    Mol Diagn Ther; 2017 Oct; 21(5):571-579. PubMed ID: 28639239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples.
    Offerman S; Prinsen CF; Knol A; Methorst N; Kamphorst J; Niemantsverdriet M
    Diagn Pathol; 2021 Aug; 16(1):70. PubMed ID: 34344387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
    Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
    Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing a New qPCR-Based System for Screening Mutation.
    Zhu J; Zhao Y; Liu M; Gonzalez-Rivas D; Xu X; Cai W; Qi H; Dai L; Wang Z; Song X; Jiang G; Yang Y
    Small; 2019 Mar; 15(9):e1805285. PubMed ID: 30677225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
    Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
    Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
    Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
    Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
    Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
    PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A PCR-Based Approach for Driver Mutation Analysis of EGFR, KRAS, and BRAF Genes in Lung Cancer Tissue Sections.
    de Oliveira Cavagna R; Leal LF; de Paula FE; Bernardinelli GN; Reis RM
    Methods Mol Biol; 2021; 2279():109-126. PubMed ID: 33683689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
    Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
    Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid clinical mutational testing of
    Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
    J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
    Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
    J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.
    García-Inclán C; López F; Pérez-Escuredo J; Cuesta-Albalad MP; Vivanco B; Centeno I; Balbín M; Suárez C; Llorente JL; Hermsen MA
    Cell Oncol (Dordr); 2012 Dec; 35(6):443-50. PubMed ID: 23055340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reporting tumor molecular heterogeneity in histopathological diagnosis.
    Mafficini A; Amato E; Fassan M; Simbolo M; Antonello D; Vicentini C; Scardoni M; Bersani S; Gottardi M; Rusev B; Malpeli G; Corbo V; Barbi S; Sikora KO; Lawlor RT; Tortora G; Scarpa A
    PLoS One; 2014; 9(8):e104979. PubMed ID: 25127237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.